1. Home
  2. AVDL vs DCO Comparison

AVDL vs DCO Comparison

Compare AVDL & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • DCO
  • Stock Information
  • Founded
  • AVDL 2015
  • DCO 1849
  • Country
  • AVDL Ireland
  • DCO United States
  • Employees
  • AVDL N/A
  • DCO N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • DCO Military/Government/Technical
  • Sector
  • AVDL Health Care
  • DCO Industrials
  • Exchange
  • AVDL Nasdaq
  • DCO Nasdaq
  • Market Cap
  • AVDL 786.3M
  • DCO 919.0M
  • IPO Year
  • AVDL 1996
  • DCO N/A
  • Fundamental
  • Price
  • AVDL $7.64
  • DCO $68.63
  • Analyst Decision
  • AVDL Strong Buy
  • DCO Strong Buy
  • Analyst Count
  • AVDL 6
  • DCO 4
  • Target Price
  • AVDL $20.00
  • DCO $73.50
  • AVG Volume (30 Days)
  • AVDL 1.7M
  • DCO 74.1K
  • Earning Date
  • AVDL 03-03-2025
  • DCO 02-13-2025
  • Dividend Yield
  • AVDL N/A
  • DCO N/A
  • EPS Growth
  • AVDL N/A
  • DCO 41.24
  • EPS
  • AVDL N/A
  • DCO 2.00
  • Revenue
  • AVDL $138,160,000.00
  • DCO $781,490,000.00
  • Revenue This Year
  • AVDL $515.63
  • DCO $4.86
  • Revenue Next Year
  • AVDL $49.32
  • DCO $5.71
  • P/E Ratio
  • AVDL N/A
  • DCO $34.39
  • Revenue Growth
  • AVDL 1523.50
  • DCO 3.78
  • 52 Week Low
  • AVDL $7.39
  • DCO $47.53
  • 52 Week High
  • AVDL $19.09
  • DCO $70.50
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 30.42
  • DCO 59.69
  • Support Level
  • AVDL $7.40
  • DCO $67.37
  • Resistance Level
  • AVDL $8.01
  • DCO $69.76
  • Average True Range (ATR)
  • AVDL 0.44
  • DCO 1.84
  • MACD
  • AVDL -0.07
  • DCO 0.27
  • Stochastic Oscillator
  • AVDL 6.93
  • DCO 78.56

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used primarily in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in worldwide technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

Share on Social Networks: